Further studies are therefore required to explore whether genetically or pharmacologically targeting this v-ATPase/TORC1-driven MSR pathway could have therapeutic applications against mitochondria-associated diseases, metabolic disorders, as well as normal aging in other organisms. The gene discussed is CRTC1; the disease is metabolic disease.